Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Syndax Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Neoplasms, Glandular and Epithelial

Renal Neoplasm

Endocrine Gland Neoplasms

Breast Neoplasms

Digestive System Neoplasms

Solid Tumors

Respiratory Tract Neoplasms

Lung Neoplasms

Neoplasms by Histologic Type

Thoracic Neoplasms

Breast Diseases

Lung Diseases

Neoplasms

Carcinoma, Non-Small-Cell Lung

Bronchial Neoplasms

Treatments

Drug: Entinostat

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02897778

SNDX-275-0140

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and pharmacodynamic parameters.

Full description

This is a single center, randomized, placebo-controlled, single dosing schedule, double-blinded study to evaluate the effect of entinostat as compared to placebo on the electrical activity of the heart in patients with advanced solid tumors. Thirty patients will be randomized in a 1:1 ratio to receive either entinostat or placebo. Study treatment will be blinded to patients and the Investigator. ECG analysts will be blinded to the patient, visit, and treatment allocation. Patients will be on study up to 30 days following study drug administration. Total study duration is expected to be 9 months. After completing this study and at the discretion of the Investigator, patients may elect to enroll into a separate continuation study (SNDX-275-0141).

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed diagnosis of a solid tumor malignancy that is not responsive to standard therapy(ies) or for which there is no approved therapy
Patients must have acceptable laboratory requirements
Left ventricular ejection fraction as measured by echocardiogram or multiple-gated acquisition scan that is above the institutional lower level of normal or greater than 50%
Has experienced resolution of toxic effect(s) of the most recent prior chemotherapy and/or prior surgical and radiation treatment
Must be able to understand and give written informed consent and comply with study procedures

Exclusion criteria

If the patient has brain metastasis, they must have stable neurologic status without the use of steroids or on a stable or decreasing dose of steroids
Presence of clinically significant gastrointestinal abnormalities that may affect the absorption of study treatments
A medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the Investigator
Patient has a concomitant cardiovascular issue that precludes adequate study treatment compliance or increases patient risk
Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study
Prior anti-cancer monoclonal antibody within 4 weeks prior to baseline
Currently enrolled in another investigational study
Has disease that is suitable for approved therapy administered with curative intent